ReviewCancers2019
Pursuing a Curative Approach in Multiple Myeloma: A Review of New Therapeutic Strategies.
Review in Cancers, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed.
- Minimal residual disease assessment by multiparameter flow cytometry in transplant-eligible myeloma in the EMN02/HOVON 95 MM trial.Blood cancer journal · 2021Trial
- [Predictive value of next-generation sequencing-based measurable residual disease quantitative stratification for early disease progression in newly diagnosed multiple myeloma after induction therapy].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2026Article
- CAR-NK cell therapy in multiple myeloma: from preclinical and clinical landscape to joining the force for treatment strategies optimization.Cell communication and signaling : CCS · 2025Review
- IgM Myeloma: A Comprehensive Overview and Practical Approach to Chemotherapeutic Management.World journal of oncology · 2025Review
- Article
- Article
- Patterns of multimorbidity in older adults with multiple myeloma: An analysis of SEER-Medicare.PloS one · 2025Article
- Review
- CAR T therapies in multiple myeloma: unleashing the future.Cancer gene therapy · 2024Review
- Multiple Myeloma: A Personal Account of My Journey With the Disease and Response to Teclistamab.Cureus · 2024Article
- Practical management of disease-related manifestations and drug toxicities in patients with multiple myeloma.Frontiers in oncology · 2024Review
- Dissecting and targeting noncanonical functions of EZH2 in multiple myeloma via an EZH2 degrader.Oncogene · 2023Article
- Assessing Pretransplant and Posttransplant Therapy Response in Multiple Myeloma Patients.Current oncology (Toronto, Ont.) · 2022Article
- Clinical Utility of Next-Generation Flow-Based Minimal Residual Disease Assessment in Patients with Multiple Myeloma.Annals of laboratory medicine · 2022Article
- Article
- Risk Stratification Before and During Treatment in Newly Diagnosed Multiple Myeloma: From Clinical Trials to the Real-World Setting.Frontiers in oncology · 2022Review
- Article
- Current State of the Art and Prospects of T Cell-Redirecting Bispecific Antibodies in Multiple Myeloma.Journal of clinical medicine · 2021Review
- Solid Organ Transplantation and Survival among Individuals with a History of Cancer.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2021Article
- Current Methods of Post-Translational Modification Analysis and Their Applications in Blood Cancers.Cancers · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Multiple myeloma (MM) is still considered an incurable hematologic cancer and, in the last decades, the treatment goal has been to obtain a long-lasting disease control. However, the recent availability of new effective drugs has led to unprecedented high-quality responses and prolonged progression-free survival and overall survival. The improvement of response rates has prompted the development of new, very sensitive methods to measure residual disease, even when monoclonal components become undetectable in patients' serum and urine. Several scientific efforts have been made to develop reliable and validated techniques to measure minimal residual disease (MRD), both within and outside the bone marrow. With the newest multidrug combinations, a good proportion of MM patients can achieve MRD negativity. Long-lasting MRD negativity may prove to be a marker of "operational cure", although the follow-up of the currently ongoing studies is still too short to draw conclusions. In this article, we focus on results obtained with new-generation multidrug combinations in the treatment of high-risk smoldering MM and newly diagnosed MM, including the potential role of MRD and MRD-driven treatment strategies in clinical trials, in order to optimize and individualize treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.